Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.

@article{Chevalier1998DocetaxelP,
  title={Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer.},
  author={Thierry Le Chevalier and Alain M Monnier and Jean Yves Douillard and Pierre Ruffi{\'e} and Xiao Song Sun and L. A. Belli and Nuhad Ibrahim and N Bougon and Jocelyne B{\'e}rille},
  journal={European journal of cancer},
  year={1998},
  volume={34 13},
  pages={2032-6}
}
The activity of the combination of intravenous docetaxel 75 mg/m2 plus cisplatin 100 mg/m2 administered every 3 weeks for 3 cycles then every 6 weeks was investigated in 51 chemotherapy naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The population was 92% male, with a median age of 54 years and median performance status of 1; 80% of patients had metastatic disease, including 37% with bone involvement. All patients received prophylactic premedication… CONTINUE READING